Nuclear Medicine and Biology
Volume 36, Issue 4 , Pages 411-417 , May 2009

Validation of an 18F-labeled biphenylalkyne as a positron emission tomography imaging agent for β-amyloid plaques

  • Shiaw-Pyng Wey

      Affiliations

    • Department of Medical Imaging and Radiological Sciences, Graduate Institute of Medical Physics and Imaging Science, Chang Gung University, Taoyuan, 333 Taiwan
    • Molecular Imaging Center, Chang Gung Memorial Hospital, Taoyuan, 333 Taiwan
    • There authors contributed equally to this work.
    • ,
  • Chi-Chang Weng

      Affiliations

    • Department of Medical Imaging and Radiological Sciences, Graduate Institute of Medical Physics and Imaging Science, Chang Gung University, Taoyuan, 333 Taiwan
    • There authors contributed equally to this work.
    • ,
  • Kun-Ju Lin

      Affiliations

    • Department of Medical Imaging and Radiological Sciences, Graduate Institute of Medical Physics and Imaging Science, Chang Gung University, Taoyuan, 333 Taiwan
    • Molecular Imaging Center, Chang Gung Memorial Hospital, Taoyuan, 333 Taiwan
    • ,
  • Cheng-Hsiang Yao

      Affiliations

    • Molecular Imaging Center, Chang Gung Memorial Hospital, Taoyuan, 333 Taiwan
    • ,
  • Tzu-Chen Yen

      Affiliations

    • Department of Medical Imaging and Radiological Sciences, Graduate Institute of Medical Physics and Imaging Science, Chang Gung University, Taoyuan, 333 Taiwan
    • Molecular Imaging Center, Chang Gung Memorial Hospital, Taoyuan, 333 Taiwan
    • ,
  • Hank F. Kung

      Affiliations

    • Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
    • ,
  • Daniel Skovronsky

      Affiliations

    • Avid Radiopharmaceuticals Inc, Philadelphia, PA 19104, USA
    • ,
  • Mei-Ping Kung

      Affiliations

    • Department of Medical Imaging and Radiological Sciences, Graduate Institute of Medical Physics and Imaging Science, Chang Gung University, Taoyuan, 333 Taiwan
    • Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
    • Corresponding Author InformationCorresponding author. Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA. Tel.: +1 215 662 3989; fax: +1 215 349 5035.

Received 9 December 2008 ,Revised 13 January 2009 ,Accepted 23 January 2009.

References 

  1. Golde TE. The Abeta hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. Brain Pathol. 2005;15:84–87
  2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353–356
  3. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306–319
  4. Mathis CA, Klunk WE, Price JC, DeKosky ST. Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies. Arch Neurol. 2005;62:196–200
  5. Mathis CA, Wang Y, Holt DP, Huang G-F, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46:2740–2754
  6. Ono M, Wilson A, Nobrega J, Westaway D, Verhoeff P, Zhuang ZP, et al. 11C-Labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease. Nucl Med Biol. 2003;30:565–571
  7. Verhoeff NP, Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, et al. In vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry. 2004;12:584–595
  8. Small GW. Diagnostic issues in dementia: neuroimaging as a surrogate marker of disease. J Geriatr Psychiatry Neurol. 2006;19:180–185
  9. Shoghi-Jadid K, Barrio JR, Kepe V, Wu HM, Small GW, Phelps ME, et al. Imaging beta-amyloid fibrils in Alzheimer's disease: a critical analysis through simulation of amyloid fibril polymerization. Nucl Med Biol. 2005;32:337–351
  10. Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7:129–135
  11. Skovronsky DB, Coleman RE, Frey K, et al. Results of multi-center, multi-ligand clinical trials with five 18F-labeled amyloid-imaging agents in Alzheimer's disease patients and healthy elderly controls. J Nucl Med. 2008;49:34p
  12. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709–7717
  13. Chandra R, Oya S, Kung MP, Hou C, Jin LW, Kung HF. New diphenylacetylenes as probes for positron emission tomographic imaging of amyloid plaques. J Med Chem. 2007;50:2415–2423
  14. Kung MP, Hou C, Zhuang ZP, Skovronsky D, Kung HF. Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease. Brain Res. 2004;1025:89–105
  15. Zhang W, Kung MP, Oya S, Hou C, Kung HF. 18F-Labeled styrylpyridines as PET agents for amyloid plaque imaging. Nucl Med Biol. 2007;34:89–97
  16. Zhang W, Oya S, Kung MP, Hou C, Maier DL, Kung HF. F-18 PEG stilbenes as PET imaging agents targeting Aβ aggregates in the brain. Nucl Med Biol. 2005;32:799–809

☆ This work was supported by a grant (no. 34004) from Chang Gung Medical Research Program.

PII: S0969-8051(09)00034-1

doi: 10.1016/j.nucmedbio.2009.01.013

Nuclear Medicine and Biology
Volume 36, Issue 4 , Pages 411-417 , May 2009

Article Tools

* Image Usage & Resolution